Author Correction: Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer

• Julia Foldi,
• Andrea Silber,
• Emily Reisenbichler,
• Kamaljeet Singh,
• Neal Fischbach,
• Justin Persico,
• Kerin Adelson,
• Anamika Katoch,
• Nina Horowitz,
• Donald Lannin,
• Anees Chagpar,
• Tristen Park,
• Michal Marczyk,
• Courtney Frederick,
• Trisha Burrello,
• Eiman Ibrahim,
• Tao Qing,
• Yalai Bai,
• Kim Blenman,
• David L. Rimm,
• Lajos Pusztai

Affiliations

Julia Foldi

Section of Medical Oncology, Yale School of Medicine

Andrea Silber

Section of Medical Oncology, Yale School of Medicine

Emily Reisenbichler

Department of Pathology, Yale School of Medicine

Kamaljeet Singh

Department of Pathology, Yale School of Medicine

Neal Fischbach

Section of Medical Oncology, Yale School of Medicine

Justin Persico

Section of Medical Oncology, Yale School of Medicine

Kerin Adelson

Section of Medical Oncology, Yale School of Medicine

Anamika Katoch

Section of Medical Oncology, Yale School of Medicine

Nina Horowitz

Department of Surgery, Yale School of Medicine

Donald Lannin

Department of Surgery, Yale School of Medicine

Anees Chagpar

Department of Surgery, Yale School of Medicine

Tristen Park

Department of Surgery, Yale School of Medicine

Michal Marczyk

Section of Medical Oncology, Yale School of Medicine

Courtney Frederick

Section of Medical Oncology, Yale School of Medicine

Trisha Burrello

Section of Medical Oncology, Yale School of Medicine

Eiman Ibrahim

Section of Medical Oncology, Yale School of Medicine

Tao Qing

Section of Medical Oncology, Yale School of Medicine

Yalai Bai

Department of Pathology, Yale School of Medicine

Kim Blenman

Section of Medical Oncology, Yale School of Medicine

David L. Rimm

Department of Pathology, Yale School of Medicine

Lajos Pusztai

Section of Medical Oncology, Yale School of Medicine